Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ME2 | P23368 | 2/20 | 0.50 |
| ▸ | ME1 | P48163 | 2/20 | 0.50 |
| ▸ | ME3 | Q16798 | 2/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12231799 | 0.90 | MAPT (0.55) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL11946893 | 0.90 | GAA (0.63) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL11947294 | 0.88 | MAPT (0.57) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL2312882 | 0.88 | MAPT (0.62) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL2309885 | 0.87 | MAPT (0.59) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL12206689 | 0.87 | MAPT (0.59) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| Acetic Acid SCHEMBL1042674 | 0.87 | MAPT (0.61) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL12206663 | 0.86 | MAPT (0.51) | MAPTKDM4ELMNAALDH1A1NPSR1 | |
| SCHEMBL12206662 | 0.85 | MAPT (0.61) | MAPTKDM4ELMNAGAAKMT2A | |
| SCHEMBL2309957 | 0.85 | MAPT (0.52) | MAPTKDM4ELMNAALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-26 | — | — | US | disclosed |
| EP-2454230-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-13 | — | — | US | disclosed |
| CN-102149681-A | Piperazine derivatives for binding and imaging amyloid plaques and their use | BAYER SCHERING PHARMA AG | 2011-08-10 | — | — | CN | disclosed |
| EP-2350000-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011006621-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006621-A1 | RADIOLABELLING METHOD USING CYCLOALKYL GROUPS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010028776-A1 | PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-18 | — | — | WO | disclosed |
| EP-2163541-A1 | Piperazine derivatives for binding and imaging amyloid plaques and their use | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250135-A1 | Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use | APP, APBA1, PSEN1 | MAPT 14/4885KDM4E 4658/4885LMNA 1212/4885 |
| US-20120189546-A1 | Radiolabelling Method Using Cycloalkyl Groups | TMEM14C, PAICS, QPCT | MAPT 2575/4885KDM4E 3499/4885LMNA 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.